U.S. markets closed
  • S&P 500

    +53.24 (+1.17%)
  • Dow 30

    +646.95 (+1.87%)
  • Nasdaq

    +139.68 (+0.93%)
  • Russell 2000

    +44.17 (+2.05%)
  • Crude Oil

    +0.26 (+0.37%)
  • Gold

    +1.80 (+0.10%)
  • Silver

    +0.14 (+0.64%)

    -0.0026 (-0.23%)
  • 10-Yr Bond

    +0.0910 (+6.78%)

    +0.0023 (+0.17%)

    +0.6600 (+0.59%)

    +1,133.37 (+2.29%)
  • CMC Crypto 200

    +26.46 (+2.10%)
  • FTSE 100

    +109.96 (+1.54%)
  • Nikkei 225

    -102.20 (-0.36%)

The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Biotech stocks turned in a lackadaisical performance last week amid earnings releases by smid-cap stocks, a few clinical readouts and data presentations at conferences and a handful of FDA verdicts.

Merck & Co., Inc. (NYSE: MRK) faced a regulatory setback, with the sNDA for Keytruda dosing updation receiving a thumbs down from the FDA. Meanwhile, after two rejections, Agile Therapeutics Inc's (NASDAQ: AGRX) Twirla contraceptive patch was approved by the FDA. Bellerophon Therapeutics Inc (NASDAQ: BLPH) was among the biggest gainers of the week following a positive clinical readout.

Here are the key catalysts that could impact trading in biotech stocks in the unfolding week.


2020 Transplantation and Cellular Therapy, or TCT, Meetings: Feb. 19-23 in Orlando, Florida
9th Annual SVB Leerink Global Healthcare Conference: Feb. 25-27 in New York

Adcom Meeting

FDA's Oncologic Drugs Advisory Committee is scheduled to discuss Eli Lilly And Co's (NYSE: LLY) sNDA for Cyramza injection for intravenous use in combination with Roche Holdings AG's Basel ADR (OTC: RHHBY) Tarceva for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations.

See Also: Why Merck Has Had Underwhelming Start To 2020

Clinical Trials

Kadmon Holdings Inc (NYSE: KDMN) will present at the TCT Meetings expanded Phase 2 data for KD025 in chronic graft-versus-host disease (Sunday).

View more earnings on IBB

Imv Inc (NASDAQ: IMV) is scheduled to present Phase 2 top-line data for DPX – Survivac and epacadostat – in ovarian cancer (Tuesday).

Menlo Therapeutics Inc (NASDAQ: MNLO) is due to present Phase 2 data for serlopitant for the treatment of chronic pruritus of unknown origin (February).



  • Epizyme Inc (NASDAQ: EPZM) (before the market open)

  • AxoGen, Inc (NASDAQ: AXGN) (after the close)

  • T2 Biosystems Inc (NASDAQ: TTOO) (after the close)

  • Theravance Biopharma Inc (NASDAQ: TBPH) (after the close)

  • Clovis Oncology Inc (NASDAQ: CLVS) (after the close)

  • Tandem Diabetes Care Inc (NASDAQ: TNDM) (after the close)

  • Guardant Health Inc (NASDAQ: GH) (after the close)

  • Halozyme Therapeutics, Inc. (NASDAQ: HALO) (after the close)

  • Medpace Holdings Inc (NASDAQ: MEDP) (after the close)

  • Orthofix Medical Inc (NASDAQ: OFIX) (after the close)

  • Retrophin Inc (NASDAQ: RTRX) (after the close)

  • Merit Medical Systems, Inc. (NASDAQ: MMSI) (after the close)

  • Revance Therapeutics Inc (NASDAQ: RVNC) (after the close)

  • Xencor Inc (NASDAQ: XNCR) (after the close)


  • Avanos Medical Inc (NYSE: AVNS) (before the market open)

  • Strongbridge Biopharma plc (NASDAQ: SBBP) (before the market open)

  • Gamida Cell Ltd (NASDAQ: GMDA) (before the market open)

  • Vericel Corp (NASDAQ: VCEL) (before the market open)

  • MannKind Corporation (NASDAQ: MNKD) (before the market open)

  • Chimerix Inc (NASDAQ: CMRX) (before the market open)

  • Lantheus Holdings Inc (NASDAQ: LNTH) (before the market open)

  • Insmed Incorporated (NASDAQ: INSM) (before the market open)

  • Intercept Pharmaceuticals Inc (NASDAQ: ICPT) (before the market open)

  • Mallinckrodt PLC (NYSE: MNK) (before the market open)

  • Amarin Corporation plc (NASDAQ: AMRN) (after the close)

  • Adamas Pharmaceuticals Inc (NASDAQ: ADMS) (after the close)

  • Akcea Therapeutics Inc (NASDAQ: AKCA) (after the close)

  • Aclaris Therapeutics Inc (NASDAQ: ACRS) (after the close)

  • Iovance Biotherapeutics Inc (NASDAQ: IOVA) (after the close)

  • Insulet Corporation (NASDAQ: PODD) (after the close)

  • Nevro Corp (NYSE: NVRO) (after the close)

  • Exelixis, Inc. (NASDAQ: EXEL) (after the close)

  • GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) (after the close)

  • Inspire Medical Systems Inc (NYSE: INSP) (after the close)

  • Repro-Med Systems, Inc. (NASDAQ: KRMD) (after the close)

  • Veracyte Inc (NASDAQ: VCYT) (after the close)

  • MacroGenics Inc (NASDAQ: MGNX) (after the close)

  • Supernus Pharmaceuticals Inc (NASDAQ: SUPN) (after the close)

  • Paratek Pharmaceuticals Inc (NASDAQ: PRTK) (after the close)

  • Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) (after the close)

  • Kura Oncology Inc (NASDAQ: KURA) (after the close)

  • Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) (after the close)


  • Harvard Bioscience, Inc. (NASDAQ: HBIO) (before the market open)

  • United Therapeutics Corporation (NASDAQ: UTHR) (before the market open)

  • Ionis Pharmaceuticals Inc (NASDAQ: IONS) (before the market open)

  • Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) (before the market open)

  • Endo International PLC (NASDAQ: ENDP) (before the market open)

  • Horizon Therapeutics PLC (NASDAQ: HZNP) (before the market open)

  • Amneal Pharmaceuticals Inc (NYSE: AMRX) (before the market open)

  • Moderna Inc (NASDAQ: MRNA) (before the market open)

  • Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) (after the close)

  • Alimera Sciences Inc (NASDAQ: ALIM) (after the close)

  • ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) (after the close)

  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (after the close)

  • Adaptive Biotechnologies Corp (NASDAQ: ADPT) (after the close)

  • Global Blood Therapeutics Inc (NASDAQ: GBT) (after the close)

  • BioTelemetry Inc (NASDAQ: BEAT) (after the close)

  • Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) (after the close)

  • Portola Pharmaceuticals Inc (NASDAQ: PTLA) (after the close)

  • Silk Road Medical Inc (NASDAQ: SILK) (after the close)

  • Editas Medicine Inc (NASDAQ: EDIT) (after the close)

  • G1 Therapeutics Inc (NASDAQ: GTHX) (after the close)

  • Opko Health Inc. (NASDAQ: OPK) (after the close)

  • Viking Therapeutics Inc (NASDAQ: VKTX) (after the close)


  • Atara Biotherapeutics Inc (NASDAQ: ATRA) (before the market open)

  • ANI Pharmaceuticals Inc (NASDAQ: ANIP) (before the market open)

  • Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) (before the market open)

  • Allogene Therapeutics Inc (NASDAQ: ALLO) (before the market open)

  • IVERIC bio Inc (NASDAQ: ISEE) (before the market open)

  • Concert Pharmaceuticals Inc (NASDAQ: CNCE) (before the market open)

  • Radius Health Inc (NASDAQ: RDUS) (before the market open)

  • SAGE Therapeutics Inc (NASDAQ: SAGE) (before the market open)

  • Intellia Therapeutics Inc (NASDAQ: NTLA) (before the market open)

  • Obalon Therapeutics Inc (NASDAQ: OBLN) (before the market open)

  • NeoGenomics, Inc. (NASDAQ: NEO) (before the market open)

  • Orchard Therapeutics PLC – ADR (NASDAQ: ORTX) (before the market open)

  • Athenex Inc (NASDAQ: ATNX) (before the market open)

  • Aimmune Therapeutics Inc (NASDAQ: AIMT) (after the market close)

  • Acceleron Pharma Inc (NASDAQ: XLRN) (after the market close)

  • Coherus Biosciences Inc (NASDAQ: CHRS) (after the market close)

  • Cara Therapeutics Inc (NASDAQ: CARA) (after the market close)

  • Glaukos Corp (NYSE: GKOS) (after the market close)

  • CareDx Inc (NASDAQ: CDNA) (after the market close)

  • CytomX Therapeutics Inc (NASDAQ: CTMX) (after the market close)

  • Collegium Pharmaceutical Inc (NASDAQ: COLL) (after the market close)

  • Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) (after the market close)

  • Five Prime Therapeutics Inc (NASDAQ: FPRX) (after the market close)

  • Otonomy Inc (NASDAQ: OTIC) (after the market close)

  • Immunomedics, Inc. (NASDAQ: IMMU) (after the market close)

  • Zynex Inc. (NASDAQ: ZYXI) (after the market close)

  • Tricida Inc (NASDAQ: TCDA) (after the market close)

  • Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (after the market close)

  • Myokardia Inc (NASDAQ: MYOK) (after the market close)

  • TRACON Pharmaceuticals Inc (NASDAQ: TCON) (after the market close)

  • Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) (after the market close)

  • ICU Medical, Incorporated (NASDAQ: ICUI) (after the market close)

  • Mylan NV (NASDAQ: MYL) (after the market close)

  • Nektar Therapeutics (NASDAQ: NKTR) (after the market close)


Passage Bio, which is developing gene therapies for central nervous system disorders, has filed to offer 7.4 million shares in an IPO to be priced between $16 and $18. The company has applied to list the shares on the Nasdaq under the ticker symbol "PASG."

IPO Quiet Period Expiry

Annovis Bio Inc (NYSE: ANVS)
AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC)
Black Diamond Therapeutics Inc (NASDAQ: BDTX)
Arcutis Biotherapeutics Inc (NASDAQ: ARQT)

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.